A phase III clinical study of atezolizumab (anti-PD-L1 antibody) combined with bevacizumab (anti-VEGF antibody) plus chemotherapy in the treatment of non-small cell lung cancer confirmed that this regimen prolongs the survival time of patients (28), providing evidence for this combined strategy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.